A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

Inclusion Criteria:

• Male or female participants aged 12 years or older

• Provision of signed and dated written informed consent, including assent for minors

• Prescribed treatment with Tezepelumab

• Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptomsconfirmed by the Investigator not to be due to alternative diagnoses

• Received at least one prescription of medium-dose to high-dose inhaledcorticosteroids (ICS) during the 52 weeks prior to enrolment date

• Use of additional asthma maintenance controller medication(s) for at least 52 weeksprior to enrolment date

• Documented history of at least 1 asthma exacerbations during the 52 weeks prior toenrolment date

• Individuals with ACQ-6 score ≥ 1.5 (indicating inadequate asthma symptom control) atenrolment or up to 12 weeks before enrolment

• Participants currently receiving care from pulmonologists and/or allergists

• Participants who are able to understand and complete the ePROs

• Availability of participants medical records for asthma exacerbation and HealthcareResource Utilization (HCRU) for the 52 weeks prior to Tezepelumab initiation

Exclusion Criteria:

• Any contraindication to Tezepelumab

• Participants on concurrent biologics for asthma at the time of receiving the firstdose of Tezepelumab will be excluded except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment)

• Participation in an observational study that might, in the Investigator's opinion,influence the assessment for the current study, or participation in aninterventional clinical trial in the last 3 months

• Pregnancy or lactation period.